Leuprorelin EP Impurity J arises from subtle synthetic or oxidative modifications within the leuprorelin backbone. Structural variance impacts retention behavior and peptide conformation. Researchers employ it to refine impurity methods and stability guidance. Applications include analytical validation, impurity profiling, and synthetic-route optimization.
CAT No: Z10-101-173
Synonyms/Alias:[8-[5-N-[Imino(1H-pyrazol-1-yl)methyl]-L-ornithine]]leuprorelin; Leuprorelin Impurity J; (2S)-1-((3S,6S,9S,12S,15R,18S)-3-((1H-imidazol-4-yl)methyl)-6-((1H-indol-3-yl)methyl)-21-(3-(1H-pyrazole-1-carboximidamido)propyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-15,18-diisobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-ethylpyrrolidine-2-carboxamide
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More